ABPI response to MHRA Delivery Plan

05 July 2021 Posted in News by Press Office

The Medicines and Healthcare products Regulatory Agency (MHRA) has published its Delivery Plan for a new era of the agency.   

This Delivery Plan sets out an exciting future for the MHRA as a leader in innovative health regulation, based on scientific excellence. New medicines and vaccines can transform the lives of patients in the UK and the MHRA plays a central role in protecting and improving patient health by enabling the earliest access to safe and effective new treatments. We look forward to continuing to work with the MHRA to deliver innovation for patients, in line with international standards. Richard Torbett

ABPI Chief Executive Richard Torbett welcomed the plan, commenting: 

“This Delivery Plan sets out an exciting future for the MHRA as a leader in innovative health regulation, based on scientific excellence.

“New medicines and vaccines can transform the lives of patients in the UK and the MHRA plays a central role in protecting and improving patient health by enabling the earliest access to safe and effective new treatments.

“We look forward to continuing to work with the MHRA to deliver innovation for patients, in line with international standards.”

TAGS
  • MHRA

Last modified: 20 September 2023

Last reviewed: 20 September 2023

The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future. 

Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.

Media enquiries

+44 (0) 20 7747 7147​​